Diabetes Drug Effects on the Skeleton

Area of Science:

• Endocrinology
• Metabolic Bone Disease
• Pharmacology

Background:

• Diabetes mellitus (Type 1 and Type 2) is linked to a higher incidence of fragility fractures.
• The precise mechanisms driving this elevated fracture risk are still under investigation.
• Anti-diabetic medications are vital for glycemic control and preventing diabetes-related complications.

Purpose of the Study:

• To comprehensively review the impact of various anti-diabetic medications on bone metabolism.
• To evaluate the evidence regarding the association between these drugs and the risk of bone loss and fragility fractures in diabetic individuals.

Main Methods:

• Literature review of studies investigating the effects of anti-diabetic medications on bone.
• Analysis of clinical data and experimental findings on drug-induced skeletal changes.
• Synthesis of information on thiazolidinediones, metformin, sulfonylureas, insulin, incretin mimetics, pramlintide, and SGLT2 inhibitors.

Main Results:

• Thiazolidinediones show detrimental effects on bone.
• Metformin and sulfonylureas appear to have neutral or potentially beneficial effects on bone.
• Insulin use is associated with increased fracture risk, possibly due to hypoglycemia and falls.
• Incretin mimetics may have beneficial effects, requiring further research.
• Bone safety concerns exist for SGLT2 inhibitors.

Conclusions:

• Different anti-diabetic medications exert varied effects on bone metabolism and fracture risk.
• Further research is needed to fully elucidate the skeletal impact of newer agents like SGLT2 inhibitors and pramlintide.
• Understanding these drug-specific effects is crucial for optimizing fracture prevention strategies in diabetes management.